Neurotensin Receptor

Neurotensin Receptor Related Products (30):

By Effects:	Inhibitors (9) Agonists (6) Antagonists (9) Activators (2) Modulator (1) Inducer (1)

Cat. No.	Product Name	Effect	Purity

HY-12802

AF38469	Inhibitor	99.28%
AF38469 is a selective, orally bioavailable Sortilin inhibitor with an IC₅₀ value of 330 nM.

HY-P0234

Neurotensin	Agonist	98.68%
Neurotensin, a gut tridecapeptide, acts as a potent cellular mitogen for various colorectal and pancreatic cancers which possess high-affinity neurotensin receptors (NTR).

HY-137322

THX-B	Antagonist	98.87%
THX-B is a potent and non-peptidic p75^NTR (neurotrophin receptor p75) antagonist. THX-B can be used in the research of diabetic kidney disease, neurodegenerative and inflammatory disorders.

HY-110155

LM11A-31 dihydrochloride		≥98.0%
LM11A-31 dihydrochloride, a non-peptide p75^NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist. LM11A-31 dihydrochloride is an amino acid derivative with high blood-brain barrier permeability and blocks p75-mediated cell death. LM11A-31 dihydrochloride reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression.

HY-115213

SORT-PGRN interaction inhibitor 1	Inhibitor	99.17%
SORT-PGRN interaction inhibitor 1 is a potent inhibitor of the sortilin-progranulin interaction with an IC₅₀ of 2 μM.

HY-148650A

(R)-Sortilin antagonist 1	Antagonist
(R)-Sortilin antagonist 1 is a sortilin antagonist that blocks the sortilin mediated apoptosis pathway by interfering with the binding of sortilin to its ligand pro-neurotrophin. (R)-Sortilin antagonist 1 can be used in the study of hearing loss.

HY-161903

Progranulin modulator-3	Inducer	99.95%
Progranulin modulator-3 (compd C40) is a brain-penetrant and orally active progranulin (PGRN) inducer. Progranulin modulator-3 can be used for neurological research.

HY-14277AR

Levocabastine hydrochloride (Standard)	Antagonist
Levocabastine (hydrochloride) (Standard) is the analytical standard of Levocabastine (hydrochloride). This product is intended for research and analytical applications. Levocabastine (R 50547) hydrochloride is a potent and selective histamine H1-receptor antagonist. Levocabastine hydrochloride is also a selective, high affinity neurotensin receptor subtype 2 (NTR2) antagonist, with a Ki of 17 nM for mNTR2. Levocabastine hydrochloride can act as a VLA-4 antagonist, interferes with conjunctival eosinophil infiltration in allergic conjunctivitis (AC).

HY-P99688

Latozinemab	Inhibitor
Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research.

HY-P2544

[Lys8, Lys9]-Neurotensin (8-13)	Activator	99.98%
[Lys8, Lys9]-Neurotensin (8-13) (JMV438), a Neurotensin analog, exerts its analgesic effects through activation of the G protein-coupled receptors NTS1 and NTS2, with K_i values of 0.33 nM and 0.95 nM for hNTS1 and hNTS2 receptors, respectively.

HY-107664A

SR 142948 dihydrochloride	Antagonist	98.6%
SR 142948 dihydrochloride is an orally active and selective non-peptide neurotensin receptor (NT) antagonist with IC₅₀s of 1.19 nM, 0.32 nM, 3.96 nM in h-NTR1-CHO cells, HT-29 cells, and adult rat brain, respectively. SR 142948 dihydrochloride antagonizes NT-induced inositol monophosphate formation in HT-29 cells with an IC₅₀ of 3.9 nM. SR 142948 dihydrochloride blocks hypothermia, analgesia and steering behavior induced by NT in vivo. SR 142948 dihydrochloride shows blood-brain permeability and can be used in study of psychiatric disorders.

HY-148650

Sortilin antagonist 1	Antagonist	99.63%
Sortilin antagonist 1 (compound 44) is a sortilin antagonist with an IC₅₀ value of 20 nM for inhibiting Neurotensin (NTS) binds to sortilin. Neurotensin is a sortilin ligand. Sortilin antagonist 1 can be used for the research of neurological disease.

HY-124673

AF40431	Inhibitor	98.00%
AF40431, the first reported small-molecule ligand of sortilin, has an IC₅₀ of 4.4 µM and a K_d of 0.7 µM . AF40431 is bound in the neurotensin-binding site of sortilin.

HY-153686

BVFP	Inhibitor	98.12%
BVFP binds to the PGRN_588–593 peptide with a K_d of 20 μM. BVFP can disrupt PGRN-SORT1 binding. BVFP also inhibits SORT1-mediated rPGRN endocytosis.

HY-107664

SR 142948	Antagonist	99.16%
SR 142948 is an orally active and selective non-peptide neurotensin receptor (NT) antagonist with IC₅₀s of 1.19 nM, 0.32 nM, 3.96 nM in h-NTR1-CHO cells, HT-29 cells, and adult rat brain, respectively. SR 142948 antagonizes NT-induced inositol monophosphate formation in HT-29 cells with an IC50 of 3.9 nM. SR 142948 blocks hypothermia, analgesia and steering behavior induced by NT in vivo. SR 142948 shows blood-brain permeability and can be used in study of psychiatric disorders.

HY-12436

NTRC-824	Antagonist	98.2%
NTRC-824 (Compound 5) is a potent, selective and neurotensin-like nonpeptide neurotensin receptor type 2 (NTS2) antagonist with an IC₅₀ of 38 nM and a K_i of 202 nM. NTRC-824 is >150-fold selectivity for NTS2 over NTS1 (K_i >30 μM).

HY-P1256C

JMV 449 acetate	Agonist	99.84%
JMV 449 acetate is a potent neurotensin receptor agonist. JMV 449 acetate shows an IC₅₀ of 0.15 nM for inhibition of ¹²⁵I-neurotensin binding to neonatal mouse brain and an EC₅₀ of 1.9 nM in contracting the guinea-pig ileum. JMV 449 acetate has highly potent and long-lasting hypothermic and analgesic effects in the mouse.

HY-153688

SORT-PGRN interaction inhibitor 3	Inhibitor
SORT-PGRN interaction inhibitor 3 (Compound 13) is a SORT-PGRN interaction inhibitor (IC₅₀: 0.17 μM). SORT-PGRN interaction inhibitor 3 can be used for research of neurodegenerative diseases.

HY-P4223

Acetyl neurotensin (8-13)
Acetyl neurotensin (8-13) is the shortest analog of neurotensin with full binding and pharmacological activities.

HY-139668

VGD071	Inhibitor
VGD071, a sortilin-targeting compound, is a promising candidate for future studies using mouse breast cancer models.

Name
Email *

	Sorry, but the email address you supplied was invalid.